Company intelligence / Profile preview

Aroa Biosurgery

Auckland, New Zealandaroa.com ↗

Ownership: Public · ARX
Development stage: Other

Overview

Aroa Biosurgery has commercialized multiple soft-tissue regenerative products based on its proprietary extracellular matrix technology. Its products have been used in over four million procedures globally with regulatory approvals in nearly fifty countries. Clinical data support improved healing rates and outcomes in complex wound care and surgical applications at a lower cost compared to human-derived or synthetic alternatives.

Therapeutic areas: DermatologyWomen's HealthOther
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

Tela Bio – licensing partner for OviTex reinforced bioscaffold products for hernia and breast surgery in the US market

Financials

Market cap: $4.3B
Total revenue: $356.9M
Enterprise value: $2.7B

Beyond the preview

Go deeper on Aroa Biosurgery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aroa Biosurgery.

Explore the full profile